GlassScriptPhysician profile
Don A Dayson
NPI 1013028638
$1,082.29
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $200 · 2023: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $119.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $178.67 | 2019 | |
| Gilead Sciences, INC. | $174.62 | 2019 | |
| Novo Nordisk INC | $160.21 | 2019-2023 | |
| Amgen INC. | $141.33 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.67 | 2019-2020 | |
| Akcea Therapeutics, INC. | $120.33 | 2020 | |
| Lilly USA, LLC | $67.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $34.03 | 2019 | |
| Hikma Pharmaceuticals USA | $22.50 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.84 | 2019 | |
| Allergan, INC. | $12.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Dayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.